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Summary Breast cancer prognosis has previously been linked to the degree of tumour vascularisation. In
order to establish additional markers for tumour angiogenesis, we have used monoclonal antibodies against the
endothelial Tie receptor tyrosine kinase to study the degree of vascularisation of breast carcinomas and the
regulation of Tie expression in the vascular endothelial cells. Antibodies were used for Tie detection and the
results were correlated with other prognostic markers. Of four monoclonal antibodies directed against different
epitopes of the Tie extracellular domain, two reacted against Tie in unfixed histopathological sections of breast
carcinomas. One of these antibodies (clone 7e8) was specific for the endothelial cells whereas the other (clone
10fl1) also reacted with basement membranes and occasional carcinoma cells. When Tie expression was studied
with the antibody clone 7e8, all 27 carcinomas, two in situ carcinomas, samples of histologically normal breast
tissue (n = 16) or normal skin or lymph node tissue (n=5) showed staining. Microvessel counts were higher in
carcinomas (median 14; range 3-27) than in fibrodenomas (median 10; range 5-18) or histologically normal
breast tissue (median 7; range 3-15, P = 0.0006). A similar result was obtained using antibodies against the
CD31 (PECAM) antigen. Microvessel counts in 7e8 staining were not significantly associated with primary
tumour size, axillary nodal status, histological grade or staining for oestrogen receptor, progesterone receptor,
Ki-67 proliferation marker or p53 oncoprotein.
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Receptor tyrosine kinases (RTKs) play key roles in signal
transduction across the plasma membrane and thus have a
significant role in regulating cellular proliferation and
differentiation (van der Geer et al., 1994). Tie (Partanen et
al., 1992) and Tek (Dumont et al., 1993) are members of a
new subfamily of endothelial cell RTKs whose extracellular
domains contain three different types of structural motifs:
immunoglobulin (Ig)-like loops, cysteine-rich epidermal
growth factor (EGF)-like domains and fibronectin type III
(FN III) domains (Maisonpierre et al., 1993; Sato et al., 1993;
Ziegler et al., 1993).
The pattern of Tie mRNA distribution in embryonic
endothelia and also in some tumours suggests that Tie plays
an important role in the development of embryonic
vasculature and possibly also in angiogenesis associated
with tumorigenesis. Tie mRNA is especially prominent in
endothelial cells during embryonic angiogenesis (Sato, et al.,
1993; Dumont, et al., 1993; Korhonen et al., 1992, 1994,
1995). Disruption of the Tie gene locus by targeted
mutagenesis was lethal. Tie-deficient embryos survived after
the time point when Tie expression normally begins, but the
mice died of haemorrhage soon after birth (Puri et al., 1995;
Sato et al., 1995). Analysis of these pups indicates that Tie
is essential for the formation of microvessels and that this
defect is cell-autonomous (Puri et al., 1995). Thus, one could
speculate that the inhibition of Tie function could have
therapeutic potential in the prevention of proliferation of the
microvascular endothelium in human solid tumours.
In adult mice, Tie mRNA has been detected in vascular
endothelium of capillaries of the lung, kidney and bone
marrow (Korhonen, et al., 1994). Tie mRNA has also been
detected in endothelia of various tissues of adult rats.
(Maisonpierre, et al., 1993). These tissues include brain,
cerebellum, heart, skeletal muscle, lung, kidney, liver, spleen,
thyroid, adrenal gland and ovary. However, the signal for
Tie mRNA is reduced in the endothelia of neural tissues of
adult rats when compared with the embryonic and neonatal
neural tissue. Expression of Tie mRNA has also been
detected in human haematopoietic progenitor cells (Batard
et al., 1996; Hashiyama et al., 1996), in leukaemia cell lines
and in some cell lines from solid tumours (Partanen et al.,
1992; Armstrong et al., 1993).
Several studies have pointed out the importance of
angiogenesis for tumour growth and progression (Folkman,
1990, 1992). Microvessel density has been shown to be an
independent parameter of the severity of tumour disease
and a predictor of prognosis of breast cancer patients in
most but not all studies addressing this issue (Weidner et
al., 1991, 1992; Bosari et al., 1992; Horak et al., 1992; Toi
et al., 1993, Axelsson et al., 1995). A similar correlation
has also been demonstrated with other human malignan-
cies, including head and neck squamous cell carcinoma
(Gasparini et al., 1993), lung adenocarcinoma (Yamazaki et
al., 1994), rectal carcinoma (Saclarides et al., 1994),
testicular germ cell tumours (Olivarez et al., 1994),
prostate cancer (Weidner et al., 1993), tumours of the
oral cavity (Williams et al., 1994) and gastric carcinoma
(Maeda et al., 1995). Various endothelial cell specific
antibodies have been used in immunohistochemistry to
quantitate blood vessels within the tumours. Antigens used
for this purpose include von Willebrand factor, CD31
(PECAM) and CD34. The purpose of this work was to
study the Tie protein in angiogenesis associated with breast
cancer. Our aim was also to evaluate the utility of Tie
detection as a measure of breast tumour angiogenesis and
the association of Tie expression with prognostic factors in
breast cancer.
Correspondence: P Salven, Department of Oncology, Helsinki
University Central Hospital, Haartmaninkatu 4C, 00290 Helsinki,
Finland
Received 28 September 1995; revised 2 January 1996; accepted 15
January 1996Tie receptor in breast cancer
P Salven et al
70
Materials and methods
Tissue sources
Freshly frozen sections of 56 tissue samples in total
containing both normal and malignant tissues were retrieved
from the histopathological files of the Department of
Pathology, University of Helsinki. The tissues examined
included 19 infiltrating ductal carcinomas, six infiltrating
lobular carcinomas, two infiltrating tubular carcinomas, one
ductal carcinoma in situ, one lobular carcinoma in situ, five
benign fibroadenomas, one adenosis, 16 samples of normal
breast tissue, two normal axillary lymph nodes and three
samples of normal breast skin.
Immunostaining
The primary antibodies used were: mouse monoclonal anti-
Tie, clones lOfl 1 and 7e8, used on sections at a concentration
of 8 pg ml- and mouse anti-CD31, clone HC1/6 (Novocas-
tra Laboratories), used on sections at a concentration of
0.66 ,ug ml-'. Staining with the primary antibodies was for
1 h at room temperature. Control stainings included
irrelevant monoclonal antibodies of the same isotype as well
as anti-Tie incubated overnight with a 5-fold molar excess of
the Tie extracellular domain expressed in baculovirus (Batard
et al., 1996).
Frozen sections (5 ,um) on slides were dried at room
temperature overnight. Following rehydration in phosphate-
buffered saline (PBS) for 5 min the sections were overlaid
with normal horse serum for 20 min before incubation with
the primary antibody. Subsequent incubation for 30 min in
biotinylated anti-mouse serum was followed by a 30 min
a
b
incubation using reagents of the Vectastain Elite ABC kit
(Vector laboratories). Peroxidase activity was developed with
3-amino-9-ethyl carbazole (Sigma) for 10 min. Finally, the
sections were stained with haematoxylin for 5 min.
Following the staining procedures, all samples were
examined by a trained pathologist. The highest microvessel
counts were assessed according to Weidner et al. (1991). After
the area of highest amount of stained microvessels (so-called
vascular hotspots) was identified by light microscopy,
individual stained microvessels were counted using a
400xmagnification field (i.e. 40x objective lens and lOx
ocular lens). Each count was expressed as the highest number
of stained microvessels identified within any high-power field
(hpf).
Statistical analysis
Staining count distributions of different groups were analysed
using Kruskal-Wallis's analysis of variance and the Mann-
Whitney test.
Results
Tie protein in histologically normal tissue
Tie protein was consistently detected in the microvessel
endothelial cells of histologically normal dermis (n= 3),
axillary lymph nodes (n=2) and breast tissue (n= 16) and
with anti-Tie antibodies clones 7e8 and lOfl (Figure la and
b). Antibody of clone lOfl1 stained breast myoepithelial cells
in some of the samples, but the staining intensity was weaker
than for endothelial cells. Microvessel counts per hpf were
C
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Figure 1 Peroxidase immunostaining of tie in normal and pathological tissues. MAb 7e8 staining ofnormal skin (a) and breast (b)
as well as invasive ductal carcinoma (c). Staining with tie antigen-blocked MAb is also shown (d). Scale bar= I00 um.
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higher when staining was performed using the clone 7E8
antibody (Table I). No specific staining was observed when
the sections were incubated with antigen-blocked antibody
instead of the primary antibodies, or with the peroxidase-
conjugated secondary antibody only.
Tie protein in breast tumours
Microvessel counts in fibroadenomas were not significantly
higher than those found in normal breast when the anti-Tie
antibody clone 7e8 was used (median, 10 per hpf vs 7
respectively, P=0.12). The microvessel counts were higher in
fibroadenomas than in histologically normal breast tissue
when anti-CD31 staining was used (median, 21 vs 15
respectively, P=0.02). Tie expression was also detected in
vessels around intraductal cancer and lobular carcinoma in
situ with the anti-Tie antibody clone 7e8.
Tie protein was detected in the endothelial cells of
microvessels in all breast carcinoma samples studied with
the clone 7e8 antibody (Figure Ic). The number of stained
microvessels was greater in breast carcinomas than in normal
breast tissue when staining was performed with the clone 7e8
antibody (median, 14 vs 7 respectively, P=0.0002). The
highest microvessel counts were also clearly greater in breast
cancer tissue than in normal breast tissue in staining for
CD31 (median, 30 vs 15 respectively, P<0.0001). No specific
staining was observed when the tumour sections were
incubated with antigen-blocked antibody or normal serum
instead of the anti-Tie antibodies (Figure Id).
In some of the invasive breast carcinoma samples the anti-
Tie antibody clone 10fl 1 also stained carcinoma cells,
basement membranes and myoepithelial cells, whereas the
clone 7e8 antibody stained vascular endothelial cells only.
The highest microvessel counts obtained by staining for Tie
protein with the two anti-Tie antibodies and for CD31 were
correlated with the primary tumour size (<2 cm vs >2 cm),
presence of axillary nodal metastases (pNO vs pN+),
histological gradus (well- or moderately differentiated vs
poorly differentiated), oestrogen and progesterone receptor
status, Ki-67 expression (lower vs higher than the median,
15%), and p53 expression (negative vs positive) among the 27
carcinomas studied, but no significant correlations were found
between these parameters and the microvessel counts.
Discussion
Several studies have suggested that the Tie protein plays an
important role in angiogenesis (Partanen et al., 1992; Sato et
al., 1993; Korhonen et al., 1994, 1995). In recent studies high
amounts of Tie mRNA and also Tie protein have been
detected in human brain tumours in contrast to the less
abundant expression of Tie mRNA or protein in the
respective normal brain tissue control samples (Kaipainen
et al., 1994; Hatva et al., 1995). These studies suggest that a
significant difference exists in the expression of Tie when the
endothelia of malignant tumours of the CNS are compared
with the endothelia of normal adult brain.
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Our results show Tie protein in the vascular endothelia of
several types of normal human tissues, including normal skin
and breast tissue. In a previously published work with human
melanoma and normal skin samples using in situ hybridisa-
tion the Tie probe hybridised very weakly with the vascular
endothelium of capillaries of normal skin, except for the
endothelium of sweat gland vessels (Kaipainen et al., 1994).
In addition, Tie expression appeared to be enhanced in areas
of inflammatory reaction around certain skin melanomas.
The differences between the results in this in situ hybridisa-
tion and the present immunohistochemical staining results
can be due to a tissue-specific variation in the level of Tie
expression, a difference in the sensitivity of detection
techniques used or translational regulation of Tie expres-
sion. The fact that the 10flf antibody cross-reacts with an
antigen expressed in ductal myoepithelium and some breast
carcinomas is not unexpected among monoclonal antibodies,
which often detect very small epitopes. Such epitopes may
resemble structures in other proteins. However, at least in
brain tumours and melanomas Tie sequences as such are only
expressed in tumour endothelia and not detected in in situ
hybridisation of the tumour cells (Hatva, et al., 1995;
Kaipainen, et al., 1994) excluding the possibility that Tie
would be aberrantly expressed at least in a significant fraction
of myoepithelial or breast carcinoma cells.
In contrast to the expression ofCD31 we did not detect Tie
expression in all microvessels of normal or malignant breast
tissue. Thus the Tie antigen may not be expressed in all
endothelial cells. A more likely explanation is, however, that
the level of Tie expression is so low that it does not allow
immunohistochemical detection. One parameter affecting the
staining intensity is obviously the thickness of the histological
sections used for staining and another concerns the possible
masking of the Tie epitope recognised by the antibodies in
tissue sections.
Tumour angiogenesis is essential for tumour growth and
metastasis and intratumoral microvessel density correlates
with prognosis in breast carcinoma and also in other human
tumours. In this study the difference in the Tie-positive
microvessel counts between the groups of invasive breast
carcinomas and normal breast tissue samples was statistically
significant (Mann-Whitney test, P=0.0002). The difference
between these groups was similar to the difference observed
when using the anti-CD31 antibody. This result suggests that
Tie might have significance as an indicator of tumour
angiogenesis and as a prognostic marker for breast cancer
patients. Although the microcapillary network of breast
carcinomas is known to be unevenly distributed, our results
do not suggest that Tie would be up-regulated in breast
carcinomas. Whether Tie is enhanced in tumour vessels
outside the central nervous system needs further study using
more quantitative methods of analysis. Thus we cannot yet
exclude scenarios of tumour treatment based on possible
differential Tie expression in normal and tumour endothelia.
However, the Tie receptor may appear on the luminal surface
ofendothelial cells and circulating Tie antigen may be present
in the blood. Such findings could preclude the use of anti-Tie
antibodies for intravascular injection because of the possible
Table I
p
Normal breast Fibroadenoma Breast cancer Kruskal- Wallis
Antibody (n = 16) (n =5) (n =27) test
7e8
Range 3-15 5-18 3-27
Median 7 10 14 <0.0006
CD31
Range 8-30 18-28 18-40
Median 15 21 30 <0.0001
Statistical analysis of microvessel counts using the anti-tie antibody clone 7e8 and the anti-
CD31 antibody in normal breast tissue, fiboradenoma and invasive breast cancer00%2 P SaMn et i
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formation of immunocomplexes with adverse side-effects.
However, it remains possible that inhibition of Tie function
by, e.g. interference with Tie-ligand interaction or Tie-specific
signal transduction, could prevent tumour angiogenesis.
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